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Over the past two decades advances in genomic technologies have transformed knowledge of the 
genetic basis of phaeochromocytoma and paraganglioma (PPGL). Though traditional teaching 
suggested that inherited cases accounted for only 10% of all phaeochromocytoma diagnosis, 
current estimates are at least three times this proportion. Inherited PPGL is a highly genetically 
heterogeneous disorder but the most frequently results from inactivating variants in genes 
encoding subunits of succinate dehydrogenase. Expanding knowledge of the genetics of PPGL 
has been translated into clinical practice by the provision of widespread testing for inherited 
PPGL. In this review, we explore how the molecular stratification of PPGL is being utilised to 
enable more personalised strategies for investigation, surveillance and management of affected 
individuals and their families. Translating recent genetic research advances into clinical service 
can not only bring benefits through more accurate diagnosis and risk prediction but also 
challenges when there is a suboptimal evidence base for the clinical consequences or 
significance of rare genotypes. In such cases, clinical, biochemical, pathological and functional 
imaging assessments can all contribute to more accurate interpretation and clinical management.   
 
Introduction 
Phaeochromocytomas and paragangliomas (PPGL) are well-vascularised tumors that arise from 
cells derived from the sympathetic (e.g., adrenal medulla or sympathetic trunk) or 
parasympathetic (e.g., carotid body, glomus tympanicum, glomus jugulare, glomus vagale etc.) 
paraganglia. According to the World Health Organization (WHO) classification (1), the term 
phaeochromocytoma is reserved exclusively for tumors of the adrenal medulla, whereas the term 
paraganglioma is recommended for tumors at all the other extra adrenal sites (though 
paragangliomas derived from parasympathetic ganglia are commonly referred to as head and 
neck paraganglioma (HNPGL) and sympathetic paraganglioma as paraganglioma). Both 
phaeochromocytomas and paragangliomas (PPGL) may contain elements of related neurogenic 
tumors such as ganglioneuroma, ganglioneuroblastoma, neuroblastoma etc. Such tumors are 
referred to as composite phaeochromocytomas or composite paragangliomas, respectively. Over 
the last two decades, advances in the genetics of phaeochromocytoma has led to improved 
molecular diagnosis, effective predictive testing of asymptomatic relatives and informed gene-
specific medical management. 
PPGL has a very high heritability rate and almost half of all cases (~40%) can be attributed to an 
inherited mutation. To date, more than 15 PPGL predisposition genes (PCGs) (including NF1, 
RET, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2, FH, MAX, EPAS1, TMEM127, DLST, 
MDH2, GOT2, SLC25A11, DNMT3A) have been implicated in hereditary PPGL and this number 
increases every year with the increasing uptake of large scale genomic sequencing (2, 3 and 
references within). Traditionally, hereditary PPGL was considered to account for approximately 
10% of cases and occur predominantly as part of three familial syndromes: Neurofibromatosis 
type 1 (NF1), caused by germline mutations in the neurofibromin 1 gene (NF1), Multiple 
Endocrine Neoplasia type 2 (MEN2) caused by germline mutations in the RET proto-oncogene 
and Von Hippel Lindau disease (VHL) caused by germline mutations in the VHL tumour 
suppressor gene (4, 5, 6). Each of these syndromes are associated with other characteristic 
phenotypic features and although each predisposes to phaeochromocytoma (including bilateral 
tumours), paragangliomas are unusual (2).  
At the start of this century, the seminal findings that inherited HNPGL and PPGL could be 
caused by germline mutations in genes encoding three subunits (SDHB, SDHC, SDHD) of 
succinate dehydrogenase were reported (7, 8, 9, 10). It quickly became apparent that the 
frequency of germline mutations in individuals with PPGL was much higher than 10% (11) and 
that many cases of apparently sporadic non-syndromic PPGL were inherited. Furthermore, these 
findings kick-started an era of PPGL gene discovery and additional PPGL predisposition genes 
were then identified. The genetic landscape of inherited PPGL is complex and heterogeneous 
(see below) but the ability to identify individuals with germline mutations has changed clinical 
practice around surveillance in patients and their relatives (12, 13). Though the impact on 
therapy is currently much more limited, gene-stratified functional studies are providing important 
insights into the molecular pathogenesis of PPGL. For example, transcriptomic analysis has 
facilitated a better understanding of the major pathways perturbed and suggested that inherited 
PPGL can be subclassified into two broad transcriptomic categories, either an angiogenic cluster 
(14) or a kinase signalling cluster (15).  Furthermore epigenetic and metabolomic profiling, 
immunohistochemistry and in vivo functional imaging can all be applied to further sub-
characterise PPGL (16). In this review we describe the molecular basis and genotype-phenotype 
correlations of inherited PPGL and outline how progress in omic technologies could lead to a 
new age of precision management and targeted therapies for PPGL. 
Genomic Landscape of PPGL     
PPGL Predisposition Genes 
More than fifteen different genes have been implicated in autosomal dominant familial PPGL to 
date. The succinate dehydrogenase genes (SDHA, SDHB,  SDHC and SDHD) are the  most 
common inherited PPGL predisposition genes, followed by mutations in genes associated with 
syndromic presentations as described above (VHL, RET and NF1 genes).  Mutations in any of the 
four SDHx genes or the SDHAF2 gene which encodes its namesake protein responsible for the 
flavination of the SDHA protein, leads to disruption of the succinate dehydrogenase enzyme in 
the citric acid cycle and accumulation of the oncometabolite succinate which drives 
tumorigenesis by inhibiting alpha-ketoglutarate dependent dioxygenase enzymes leading to 
hypermethylation and pseudohypoxia (17) (see Figure 1). Mutations in these genes predispose to 
multi-focal and synchronous PPGL which can be parasympathetic arising in the head and neck or 
mediastinum or sympathetic and develop in the abdomen and pelvis. SDHx mutations also 
predispose to non-PPGL tumours including gastrointestinal stromal tumours, renal cell 
carcinoma and rarely pituitary tumours (12).  
Mutations in further citric acid cycle genes have been implicated in hereditary PPGL including 
germline mutations in the fumarate hydratase (FH) gene (associated with hereditary 
leiomyomatosis, renal cell carcinoma and rarely phaeochromocytoma) (18, 19). Malate 
Dehydrogenase (MDH2) (implicated in rare cases of familial PPGL) (20) and more recently 
germline mutations in the gene encoding the mitochondrial 2-Oxoglutarate/Malate Carrier 
(SLC25A11) (21) and in a gene encoding a component of the oxoglutarate dehydrogenase 
complex; dihydrolipoamide S-succinyltransferase  (DLST), have also been implicated in rare 
cases of familial PPGL (22). The mechanisms of tumorigenesis provoked by citric acid cycle 
mutations (namely hypermethylation and pseudohypoxia) have also recently led to the discovery 
that a gain of function mutations in a DNA methyltransferase gene (DNMT3A) is also rarely be 
implicated in familial PPGL (23). 
Beyond citric acid cycle predisposition genes and syndromic causes of familial PPGL, mutations 
in genes involved in the regulation of kinase pathways including; TMEM127, a gene which 
encodes a transmembrane protein involved in modulation of the mTOR pathway (24) and 
mutations in the MYC associated factor X (MAX ) gene (25), the Hypoxia Inducible Factor-2 
alpha subunit gene (HIF2A/EPAS1)  (26) and EGLN1/PHD2 (27) complete the list of the genes 
currently proposed to be implicated in familial PPGL.  
Somatic events and tumourigenic pathways in PPGL 
The somatic genetic and epigenetic events in both inherited and sporadic PPGL tumorigenesis 
have been delineated by targeted and genome-wide sequencing studies and epigenetic and 
metabolomic investigations. A large number of genes have been reported to harbour germline 
(see above and/or somatic mutations in PPGL but PPGL are noteworthy because each tumour 
typically has a low mutation load and in many cases only a single driver mutation (germline or 
somatic) is detected (28). For inherited PPGL the germline mutation usually inactivates a tumour 
suppressor gene (e.g. NF1, VHL, SDHX, MAX, FH, TMEM127 etc.) and the PPGL contains a 
somatic event (giving “two hits”) such as a large chromosomal deletion, somatic mutation or 
promoter methylation with transcriptional silencing that inactivates the wild-type allele (29, 28). 
In sporadic PPGL, the most common copy number abnormalities are loss at chromosome 1p, 3p, 
3q 11p, 17, 21q and 22q loss (28) which include the VHL (3p25) and NF1 (17q11.2) gene 
locations. Overall, somatic inactivating mutations in NF1 and VHL or somatic activating 
mutations in RET and EPAS1 occur in ~25% of sporadic PPGL but somatic mutations in other 
inherited PPGL such as SDHx or FH are rare (28, 30).  A number of genes that have not been 
implicated in inherited PPGL have been reported to be somatically mutated in PPGL including 
HRAS, BRAF, SETD2, FGFR1, TP53, ATRX, ARNT , IDH1, H3F3A, MET, CSDE1. In addition , 
MAML3 fusion genes and structural rearrangements in telomerase reverse transcriptase (TERT) 
have been described  (28, 31). Interestingly, as often each PPGL includes a single driver 
mutation and somatic HRAS mutations occur in ~10% of sporadic PPGL but not inherited PPGL, 
it has been suggested that if a HRAS mutation is detected by somatic mutation profiling, the risk 
of inherited disease will be low (32).  
Though a large number of genes have been implicated in the molecular pathogenesis of inherited 
and sporadic PPGL, many can be linked to a number of key signalling pathways. A decade ago, 
transcriptomic analysis of PPGL suggested two distinct subcategories comprising Cluster 1 that 
was characterised by upregulation of hypoxia signalling pathways and Cluster 2 in which there 
was no hypoxic signal but kinase signalling pathways were upregulated (14). Unsurprisingly, 
tumours with mutations in VHL and HIF2A/EPAS1 (pVHL is a negative regulator of the hypoxia 
induced transcription factors HIF-1 and HIF2) map to Cluster 1. In addition, SDHX, FH, MDH, 
and SLC25A11-mutated tumours fall into Cluster 1 (30). In these cases the intracellular 
accumulation of the relevant oncometabolite (succinate, fumarate etc.) inhibits hydroxylation of 
key HIF1A/HIF2A proline residues that are required for pVHL to bind and initiate proteasomal 
degradation of the HIF-alpha subunits ((PPGL-associated mutations in HIF2A usually affect 
binding of pVHL to this proline residue (P531)) (33, 34, 35). The pVHL protein has a key role in 
targeting the HIF2A protein for proteasomal degradation and somatic inactivating mutations in 
VHL and activating mutations in HIF2A will both result in stabilisation of HIF2A and activation 
of hypoxic gene response pathway (26, 36). The oncometabolites also inhibit other alpha-
ketoglutarate-dependent enzymes including the TET (ten-eleven translocation) proteins that 
actively demethylate DNA demethylation and SDHX, FH, MDH, and SLC25A11-related tumours 
are characterised by genome methylation (16, 21). Recently, it has been reported that these 
oncometabolites also inhibit homology-dependent DNA repair (HDR) pathways by causing 
aberrant hypermethylation of histone 3 lysine 9 at DNA breaks resulting in impaired HDR (37, 
38) (see Figure 1).  Thus though Cluster 1 tumours are characterised by activation of a 
pseudohypoxic gene response, there is heterogeneity for other pathways including DNA 
methylation and DNA repair (see Table 1).   
Within Cluster 2 there is also genetic and pathway heterogeneity. Mutations in RET, NF1, 
TMEM127, MAX and HRAS, deregulate to varying degrees kinase pathways including 
PI3K/AKT, RAS/RAF/ERK amf mTORC1 pathways (REFS). Wnt-pathway alterations have 
been associated with somatic CSDE1 mutations and MAML3 fusion events (28) (see Table 1). 
Other somatic events include TERT promoter mutations and mutations in ATRX, an epigenetic 
regulator (39, 40).  
Demographic and Phenotypic Correlations in Inherited PPGL 
The presence of non-neoplastic syndromic features and non-PPGL tumour types can lead to 
suspicion of a syndromic diagnosis (e.g. medullary thyroid cancer in MEN2, haemangioblastoma 
and VHL disease etc. which can then be confirmed by diagnostic testing. Similarly the presence 
of a family history of PPGL or HNPGL or of bilateral or multiple PPGL will invariably suggest 
the presence of an underlying genetic predisposition and trigger genetic testing. However a range 
of other clinical, biochemical, pathological and imaging features can also be used to inform 
predictions about the likelihood of a genetic cause: 
i) Age: A young age at presentation is associated with a higher risk of a germline pathogenic 
variant in a PPGL gene. Diagnostic yields as high as 80% have been reported in paediatric 
populations with PPGL, compared to 30-40% in adult populations (41).  
ii) Tumour location: Extra adrenal location is major phenotypic predictor of germline SDHx 
genes mutations (42). The diagnostic yield for pathogenic variants in inherited PPGL genes in 
individuals with a paraganglioma was can be six times higher than in those with an isolated 
adrenal phaeochromocytoma (43).  
 iii)  Tumour secretory phenotype: Biochemical testing is an essential step in the diagnostic 
pathway for PPGL and current guidelines recommend urinary or plasma metanephrines and 
plasma 3-methoxytyramine (3MT) as the first line biochemical tests in the diagnosis of PPGL 
(44).  The pattern of catecholamine secretion from a PPGL is determined by paraganglial cell 
differentiation and therefore biochemistry can be used to predict genotype and or malignant 
potential. Pseudohypoxic or ‘Cluster 1’ PPGL are characterised by poor differentiation of 
paraganglia cells and reduced expression of a catecholamine conversion enzyme called 
Phenylethanolamine N-methyltransferase (PNMT). Reduced expression of this enzyme affects 
the conversion of noradrenaline to adrenaline, resulting in a predominant noradrenergic secretory 
pattern in tumours harbouring mutations in the ‘cluster 1’ genes (45). In addition to reduced 
expression of PNMT, SDHx mutated tumours also have reduced activity of the enzyme 
dopamine-β-hydroxylase, responsible for the conversion of dopamine to norepinephrine in the 
catecholamine synthesis pathway. Therefore elevated levels of dopamine or its metabolite 3- 
methoxytyramine is also a characteristic biochemical signature of SDH deficient PPGL (46). 
Elevated dopamine can be viewed as a surrogate marker for poor paraganglia cell differentiation 
and elevated levels of 3-methoxytyramine has been validated as an independent predictor of 
malignant disease (45).  Finally, SDHx mutations can also affect the expression and or activity of 
the rate limiting enzyme in catecholamine synthesis; tyrosine hydroxylase, explaining why non-
secretory PPGL are also more commonly associated with SDHx gene mutations (46). In contrast,  
‘cluster 2’ tumours are predominantly driven by mutations in kinase signalling genes, have a 
more mature phenotype associated with increased expression of PNMT and a mixed or 
predominately adrenergic secretory pattern (45)(28).  
 iv) Malignancy: About 10% of PPGL are malignant (higher in paraganglioma than in 
phaeochromocytoma). Germline SDHx, particularly SDHB mutations, are associated with a 
higher risk of malignancy and a recent meta analysis has suggested a rate of metastatic PPGL of 
48.9% in SDHB mutation carriers compared to a rate of 8.9% in non-SDHB mutation carriers 
(30). Two rarer PPGs linked to malignant PPGL are FH and SLC25A11 (47, 21).  An increased 
risk of aggressive and metastatic disease has been associated with somatic ATRX mutations, 
MAML3 fusions and TERT activation (28).   
v)  Immunohistochemistry: Histopathological examination is not a reliable predictor of 
malignancy in PPGL and the diagnosis of malignancy is dependent on the presence of distant 
metastases (48). However immunohistochemistry (IHC) is an important tool for detecting or 
confirming inherited PPGL. Biallelic inactivation (i.e. a germline mutation and somatic “second 
hit”) of any of the SDHx genes will typically destabilise the SDH enzyme complex resulting in 
proteolytic degradation of the anchor SDHB protein, which can be detected by loss of staining 
for the SDHB protein by IHC (49). Thus, SDHB IHC can be used to identify PPGL harbouring 
an SDHx mutation and as a functional tool for assessing the pathogenicity of uncharacterised or 
novel SDHx variants. IHC for SDHA expression can predict the presence of pathogenic SDHA 
variants specifically in the SDHA gene and can be utilised in clinical practice (50). The 
interpretation of variants in FH is facilitated by IHC to detect loss of expression of the fumarate 
hydratase protein (by FH IHC) or by the detection of protein succinylation (a post-translational 
modification resulting from the reaction of excess fumarate with cysteine residues) shown by 
positive staining to S-(2-succinyl)-cysteine (2SC) (51). IHC may also be utilised for other 
hereditary causes of PPGL including assessment of MAX expression and IHC for the 
membranous expression of carbonic anhydrase 9 (CA-9) in the assessment of germline or 
somatic VHL gene mutations (52). In some cases loss of SDHB expression may not result from a 
SDHX mutation but from a germline or somatic VHL gene mutation (53).  
 
5. Personalised Medicine Approaches in Pheochromocytoma and Paraganglioma 
The molecular stratification of patients with PPGL through germline and somatic testing opens 
up the possibility of genotype-driven personalised therapy. This might be considered from a 
variety of perspectives (see below) and for individuals who do or do not have a pathogenic 
variant in a PPG but also, the less definitive situation in which a VUS is detected or inherited 
PPGL is suspected but molecular confirmation is not available (see Table 2). As described 
above, there are a number of strategies available to enable precision medicine. including genetic 
testing, immunohistochemistry and functional imaging. What is the current and future role of 
these in clinical practice? 
1.   The Who and How of genetic testing: In view of the high diagnostic yield of germline testing 
in individuals with PPGL, it has been argued that a universal genetic testing strategy should be 
employed. However currently (though this is likely to change as genetic testing becomes less 
expensive) most centres practice some form of selective testing. Patients with features of an 
inherited syndrome, family history of PPGL (or a relevant tumour e.g RCC or GIST) or multiple 
tumours (e.g. two PPGL or a PPGL and a related tumour such as HNPGL, wtGIST, RCC etc.) 
should be routinely offered testing. Based on the genotype-phenotype correlations discussed 
above, those with an extra-adrenal location (sympathetic paraganglioma) or metastatic disease 
also qualify for testing. For patients with an isolated pheochromocytoma, the decision to test is 
usually based on a younger age at diagnosis (e.g. <60 years but some centres may have lower age 
limits) but incorporation of additional factors such as biochemical profile or 
immunohistochemistry (see below) may influence the decision to test older patients. Most 
centres will offer testing with a large panel of PPGL susceptibility genes (either a custom gene 
panel or exome sequencing with “virtual gene panel”) that will typically include major PPGL 
genes  (NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, FH, MAX, EPAS1, TMEM127) but not 
necessarily rarer susceptibility genes.  Hence if first-line testing is negative then inclusion of 
additional genes or further analysis for cryptic mutations that may not be detected by routine 
testing (e.g. for VHL (54), immunohistochemistry or tumour testing may be considered. 
Combined germline and tumour mutation analysis has resulted provided a diagnostic yield for 
germline/somatic driver mutation of ~80% (30) but not all driver events are genetic, somatic 
epimutations in the promoter region of the SDHC gene have been reported wtGIST and 
occasionally in PPGL (55, 56).  
The detection of a germline or genetic variant may not provide an unequivocal diagnosis, 
Resolving the pathogenicity of rare variants of uncertain significance (VUS), particularly in less 
frequently tested genes can be challenging but may be facilitated by IHC (see above), 
segregation analysis in familial cases, somatic testing (e.g. by finding LOH or somatic variant 
that is not usually detected in familial disease) or functional imaging (see below).  
In most centres germline testing is performed in the first instance as, though tumour testing can 
have some advantages, in most cases only formalin-fixed material is available for analysis. 
2. Role of Immunohistochemistry: in addition to its utility in variant interpretation (see above), 
can be used to screen for PPGL that require germline testing but have not been selected. Thus in 
some centres, SDHB IHC is performed in older patients with isolated phaeochromocytoma. 
Though such an approach could be extended to screen for MAX and FH-related 
phaeochromocytoma, these are much rarer.  
3. Role of functional imaging for PPGL Precision Medicine: Nuclear imaging techniques can be 
utilised as adjuncts to morphological cross sectional imaging studies and have diagnostic and 
theranostic utility in the management of PPGL.  Nuclear imaging tracers specific for PPGL can 
be sub-classified based on their target ligand into three groups; i) catecholamine storage and 
synthesis (123I-metaiodobenzylguanidine, 18F-fluorodopamine (18F-FDA), and 18F-
fluorodihydroxyphenylalanine (18F-FDOPA), ii) somatostatin receptor (111Indium-pentetreotide 
and Gallium-68 DOTA-conjugated peptide (68Ga DOTATATE), iii) glucose metabolism (18F-
Fluorodeoxyglucose (18F-FDG). The selection of the most appropriate tracer for surveillance or 
diagnosis of PPGL is influenced by the patient genotype and the associated interplay with 
tumour biology, tumour location and tumour secretory pattern, all of which influence the 
expression of receptors targeted by functional imaging tracers, giving rise to a so called 
‘functional imaging phenotype’ (57). 
The tracer 123/131 I-metaiodobenzylguanadine (MIBG) is taken up by the noradrenaline 
transporter (NET) however; the sensitivity of 123/131 I-MIBG scintigraphy is affected by 
tumour de-differentiation resulting in loss of NET expression, therefore increasing the risk of 
false negative results using 123/131 I-MIBG scintigraphy. Furthermore, mutations in SDHx are 
also associated with downregulation of the NET transporter, affecting the sensitivity of 
123/131I-MIBG scintigraphy in SDH-deficient tumours (58). Therefore, current 
recommendations advice that 123/131I-MIBG scintigraphy should be reserved for those cases 
being investigated for suitability of treatment with 123/131I-MIBG radionuclide therapy rather 
than for  surveillance, diagnosis or the detection of occult metastases particularly in those 
patients with suspected SDHx mutations (59). Similar issues with sensitivity are seen with the 
tracer 18F-FDA, also taken up by the NET transporter.  The imaging tracer 18F-FDOPA is taken 
up via neutral amino acid transporter system L and the sensitivity of 18F-FDOPA PET CT is 
notably reduced in patients with SDHx mutations and although the exact mechanism for this is 
not fully understood it is thought to relate to the truncated citric acid cycle and the impaired 
secretory status of SDHx mutated tumours (57). 
The sensitivity of 18F-FDG PET-CT also differs depending on the driver genetic mutation, as 
cluster 1 tumours exhibit attenuated glycolysis and demonstrate increased standard uptake values 
(SUV) of 18F- FDG due to increased expression of glucose transporters and glycolytic enzymes 
(60). 
The tracer 68 Ga-DOTATATE can be used to identify tumours expressing somatostatin receptor 
subtype 2 and a recent meta-analysis of 8 studies reviewing the sensitivity of functional imaging 
modalities for the detection of PPGL of unknown genotype, demonstrated that 68-Gallium 
DOTATATE PET CT had a pooled sensitivity of 93% and was superior to 18F FDG PET CT, 
18F-FDOPA and 123/131 I-MIBG scintigraphy (61). An earlier meta-analysis also reported a 
superior sensitivity for the detection of SDHx mutated PPGL using 68-Gallium DOTATATE 
PET CT compared to 18F FDG PET CT. (62) 
Therefore 68-Gallium DOTATATE PET CT is now recommended as the imaging modality of 
choice for staging and surveillance in patients with SDHx mutated PPGL or sporadic or 
metastatic PPGL (63). In addition to the diagnostic role, 68Ga-DOTATATE PET/CT can also 
predict the efficacy of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE 
for patients with metastatic PPGL. In centres where 68-Ga-DOTATATE PET CT is not 
available, 18F FDG PET CT would be a reasonable alternative tracer to consider for staging and 
surveillance in patients with SDHx mutated PPGL. On the contrary, 68-Ga-DOTATATE PET 
CT has demonstrated poor sensitivity in patients with EPAS1 mutations and therefore 18F-
DOPA PET CT is recommended as the first line functional imaging modality for surveillance in 
patients with EPAS1 mutations or patients with cluster 2 gene mutations (RET, MAX, NF1) who 
are at higher risk of phaeochromocytoma owing to the high tumor to background normal adrenal 
uptake of this tracer compared to 68-Ga-DOTATATE (63, 64) 
3. Surgical management: the primary treatment of a single localised PPGL will generally be 
surgical but a clinical or molecular diagnosis of inherited PPGL prior to surgery may influence 
the surgical strategy. For example in individuals with MEN-2A/B or VHL disease with 
phaeochromocytoma, who are at risk of a further tumour in the other adrenal gland, an adrenal 
cortical sparing approach can be preferable (65). When a PPG mutation has been detected the 
risks of further primary tumours and of malignant disease will need to be considered and is 
informed by established genotype-phenotype correlations.  
4. Post surgical follow up: Individuals with PPGL and a PPG mutation should be designated for 
lifelong follow to enable early detection of further primary PPGL and non-PPGL tumours and 
metastatic disease, the specific risks of these events is dependent on the PPG implicated. For 
example risk of metastatic disease is highest with SDHB mutations (42) but metastatic disease 
developed in an individual with a germline SDHA mutation more than two decades after the 
initial paraganglioma (66). Surveillance protocols for non-PPGL tumours in inherited 
multisystem inherited cancer syndromes such as VHL disease, MEN2, HLRCC and NF1 have 
been described elsewhere (67, 68, 69, 70). For individuals with germline mutations in non-
syndromic genes (SDHX, MAX, TMEM127 and rarer genes) there is a recent trend towards 
moving to a more gene specific approach to surveillance up of affected individuals and 
asymptomatic gene carriers (see Table 3).  
5. Management of metastatic disease: widely used first line treatments for metastatic PPGL 
include cytotoxic chemotherapeutic regimes (cyclophosphamide, vincristine and dacarbazine) 
targeted therapies such as sunitinib and temozolomide (71) or radiopharmaceutical options such 
as  131I-MIBG, 90Y- and 177Lu-DOTATATE (72, 73). In general these have been applied 
irrespective of the genetic background but increasing evidence for genotype-specific differences 
in the cellular pathways dysregulation in inherited PPGL (e.g. hypoxia-gene response pathways 
in VHL and SDHx-mutated PPGL and DNA methylation and chromatin regulation in TCA gene 
mutations (see above)) is paving the way for molecularly-stratified clinical  trials targeting 
specific mechanisms of tumorigenesis. Angiogenic inhibition by tyrosine kinase inhibitors such 
as sunitinib and sorafenib are widely used for the treatment of metastatic RCC in VHL 
inactivation is frequent (74). More precise targeting of hypoxic gene response pathways is 
promised by the development of HIFa-antagonists such as PT2977 (75) which is currently being 
evaluated in VHL disease patients with RCC and might prove to be an option for metastatic 
Cluster 1 PPGL. The demonstration of genome hypermethylation and inpaired HDR pathways in 
SDHx and FH-related tumorigenesis suggests a potential role for demethylating agents and 
PARP inhibitors (37). If such approaches prove to be successful then we would expect that 
genotype-driven treatment for metastatic PPGL will become an established part of clinical care.  
 6. Cascade testing and surveillance of at risk relatives. The identification of a pathogenic PPG 
variant in an affected individual enables genetic testing of their relatives to determine tumour 
risks and need for tumour surveillance. As for affected individuals (see above) there is an 
increasing trend towards genotype-specific surveillance of asymptomatic gene carriers identified 
through familial testing. Though all the major causes of inherited PPGL are caused by 
monoallelic pathogenic variants, for germline mutations in SDHD, SDHAF1 and MAX there are 
important parent-of-origin effects on tumour risks which mean that maternal transmission of a 
pathogenic variant is associated with a low risk of clinical disease and this is reflected in the 
gene-specific surveillance programmes (see Table 3). 
Conclusion 
Over the past two decades our knowledge of the genetic basis of PPGL has been transformed and 
aspects of the clinical management PPGL are increasingly being influenced by the results of 
genetic testing. With falling costs of genomic technologies we anticipate that genetic testing for 
PPGL will become eventually universal and more comprehensive (e.g. by application of 
germline whole genome sequencing and tumour testing for somatic mutations) However, in 
order for PPGL to become an exemplar of personalised medicine important challenges remain in 
particular (i) improving variant interpretation to reduce the number of VUSs, (ii) accurate tumour 
risk prediction for each PPGL gene in various clinical settings, (iii) establishing the optimal 
genotype-specific surveillance protocols that enable both accurate early tumour diagnosis 
without undue health care costs or iatrogenic risks, (iv) elucidating what the optimal targeted 
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NF1 Both 3% 
9% 
- - - + - 
RET Both 6% 
9% 
- - - + - 
VHL Both 4% 3% + - - - - 
SDHA Germlin
e 
1% Rare + + + - - 
SDHB Germlin
e 
9% Rare + + + - - 
SDHC Germlin
e 
1% Rare + + + - - 
SDHD Germlin
e 
2% Rare + + + - - 
FH Germlin
e 
1% Rare + + + - - 
HIF2A Both Rare 5% + - - - - 
MAX Germlin
e 





0.6% Rare - - - + - 
HRAS Somatic - 
10% 
- - - + - 
CSDE1 
Somatic - 2% - - - - + 
 






Table 2: Aspects of PPGL management that are influenced by results of genetic testing  
  Germline 
pathogenic variant 
(PV) detected 
Germline VUS in 
PSG or significant 
risk factors* 
No genetic variant 
and no risk factors 
Proband follow up for 
recurrence/metastatic 
disease 





Yes - specific 
surveillance 
dependent on 
relevant gene  
Occasionally 
applicable if strong 
suspicion of a 
syndromic cause 
 No* 
Genetic testing of 
relatives 




relatives for PPGL 
Screening offered 
to PV positive 
individuals; tailored 
to specific gene 
Potentially 






First line therapies  






clinical trials (see 
text), 
Usually as per 
standard protocols 
As per standard 
protocols 
*assuming no clinical or pathological features that suggest a genetic cause is likely 
 
  
Table 3: Examples of genotype-specific surveillance for asymptomatic mutation carriers of non-
syndromic PPGL  
Gene Recommended surveillance 
SDHB ·Annual clinical review and biochemistry 
·Abdominal imaging at baseline and if normal every 12-24 months 
·MRI/CT of neck, thorax at baseline and if normal every 3 years 
SDHD ·Screening should only be offered to patients who have a paternally 
inherited SDHD variant * 
·Annual clinical review and biochemistry 
·Abdominal imaging and MRI/CT of neck, thorax at baseline and if 
normal every 3 years 
SDHC ·Annual clinical review and biochemistry 
·Abdominal imaging and MRI/CT of neck, thorax at baseline and if 
normal every 3 years 
SDHA ·Annual clinical review and biochemistry 
·Abdominal imaging and MRI/CT of neck, thorax at baseline and if 
normal every 3-5years 
 
 Recommended surveillance 
MAX** ·Screening should only be offered to patients who have a paternally 
inherited MAX variant 
·Annual clinical review and biochemistry 
·Abdominal imaging  at baseline and if normal every 3 years 
·MRI  of neck, thorax at baseline and if normal every 5 years 
TMEM127** ·Annual clinical review and biochemistry 
·Abdominal imaging* at baseline and if normal every 3 years 
·MRI of neck, thorax at baseline and if normal every 5 years 
SDHAF2 ·Screening should only be offered to patients who have a paternally 
inherited SDHAF2 variant 
·Annual clinical review and biochemistry 
·Abdominal imaging  at baseline and if normal every 3 years 








Figure1: Illustration of how pathogenic variants in citric acid cycle genes result in enzyme 
dysfunction in the mitochondria resulting in accumulation of  oncometabolites (shown in red) 
(e.g. succinate with succinate dehydrogenase subunit gene mutations). The oncometabolites and 
inhibit 2-oxyglutarate dependant enzymes (including demethylase enzymes and prolyl 
hydroxylase enzymes)  resulting in  pseudohypoxia and DNA hypermethylation phenotypes and 
impair homology-dependent DNA repair, promoting tumour development. 
 
 
IDH- isocitrate dehydrogenase 
SDH-Succinate dehydrogenase 
FH- Fumarate hydratase 
MDH-Malate dehydrogenase 
OGC-oxoglutarate carrier 
TET- Ten-eleven translocation enzyme 
PHD- prolyl hydroxylase enzymes 
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